Scandion Oncology Q3 2022: Back to the basics - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Scandion Oncology Q3 2022: Back to the basics - Redeye

{newsItem.title}

Redeye comments on Scandion Oncology’s Q3 2022 report, some one month after the company has recruited the first of up to 36 patients to its phase II CORIST part 3 dose-finding arm. We adjust our estimates and fair value range to reflect current capital market conditions.

Länk till analysen i sin helhet: https://www.redeye.se/research/863687/scandion-oncology-q3-2022-back-to-the-basics?utm_source=finwire&utm_medium=RSS

Nyheter om Scandion Oncology

Läses av andra just nu

Om aktien Scandion Oncology

Senaste nytt